Voyageur Pharmaceuticals Ltd. News

Voyageur Pharmaceuticals Announces Publication of the Jubilee Mountain NI 43-101 Report & Staking of Falcon Claims- Copper Polymetallic Assets

February 16, 2022 (Source) — Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the completion of […]


Voyageur Pharmaceuticals Announces IRR of 137% and NPV of $344 Million from Preliminary Economic Assessment for the Frances Creek Pharmaceutical Barium Project

January 11, 2022 (Source) — Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV: VM) is pleased to announce the results […]


Voyageur Pharmaceuticals Provides Update on PEA Progress & Takes a Major Step Towards Production Start Up

December 6, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) has a preliminary economic assessment (PEA) on its Frances Creek project […]


Voyageur Pharmaceuticals & Summit Nanotech Corporation Sign Memorandum of Understanding for a Technology Development Project

November 8, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the signing  of a non-binding Memorandum of […]


Voyageur Pharmaceuticals Ltd., Announces The Completion of a New Scientific Advisory Board With World Class Leading Physicians

October 18, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC:VYYRF) (the “Company” or “Voyageur”) develops, manufactures and will commercialize high-performance […]


Voyageur Pharmaceuticals Ltd., Announces The Creation of a New Scientific Advisory Board With World Class Leading Physicians

September 14, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) develops, manufactures and will commercialize high-performance cost effective […]